N+1 Singer Boosts Oxford BioMedica plc (OXB) Price Target to GBX 8.70
Oxford BioMedica plc (LON:OXB) had its price objective lifted by N+1 Singer from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) in a research report report published on Thursday. N+1 Singer currently has a hold rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently weighed in on OXB. Jefferies Group LLC reaffirmed a buy rating and set a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. Shore Capital reaffirmed a not rated rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th.
Shares of Oxford BioMedica plc (OXB) opened at 8.58 on Thursday. The firm’s market cap is GBX 264.61 million. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 11.50. The company’s 50 day moving average is GBX 7.58 and its 200-day moving average is GBX 5.41.
In other news, insider Martin Diggle acquired 660,000 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average price of GBX 9 ($0.12) per share, with a total value of £59,400 ($77,384.05). Also, insider Lorenzo Tallarigo acquired 49,033 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average cost of GBX 5 ($0.07) per share, with a total value of £2,451.65 ($3,193.92). Insiders have purchased 1,011,980 shares of company stock valued at $8,448,961 in the last ninety days.
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.